These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 1832237
1. Immune response to hepatitis B virus proteins: relevance of the murine model. Milich DR. Semin Liver Dis; 1991 May; 11(2):93-112. PubMed ID: 1832237 [Abstract] [Full Text] [Related]
2. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Milich DR, McLachlan A, Thornton GB, Hughes JL. Nature; 1991 May; 329(6139):547-9. PubMed ID: 2443856 [Abstract] [Full Text] [Related]
3. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. II. Synthetic Pre-S(2) immunogen. Milich DR, Jones JE, McLachlan A, Bitter G, Moriarty A, Hughes JL. J Immunol; 1990 May 01; 144(9):3544-51. PubMed ID: 1691763 [Abstract] [Full Text] [Related]
4. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. Wirth S, Guidotti LG, Ando K, Schlicht HJ, Chisari FV. J Immunol; 1995 Mar 01; 154(5):2504-15. PubMed ID: 7868916 [Abstract] [Full Text] [Related]
5. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG, Kadoshnikov YP, Kalinina TI, Smirnov VD, Wahren B. Biochemistry (Mosc); 1998 May 01; 63(5):551-8. PubMed ID: 9632891 [Abstract] [Full Text] [Related]
6. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. J Immunol; 1986 Jul 01; 137(1):315-22. PubMed ID: 2423607 [Abstract] [Full Text] [Related]
7. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. Schödel F, Peterson D, Hughes J, Wirtz R, Milich D. J Biotechnol; 1996 Jan 26; 44(1-3):91-6. PubMed ID: 8717391 [Abstract] [Full Text] [Related]
8. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Antiviral Res; 2012 Oct 26; 96(1):59-64. PubMed ID: 22884884 [Abstract] [Full Text] [Related]
13. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. Riedl P, Wieland A, Lamberth K, Buus S, Lemonnier F, Reifenberg K, Reimann J, Schirmbeck R. J Immunol; 2009 Jul 01; 183(1):370-80. PubMed ID: 19542448 [Abstract] [Full Text] [Related]
14. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. J Immunol; 1998 Nov 01; 161(9):4520-9. PubMed ID: 9794377 [Abstract] [Full Text] [Related]
15. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Li X, Yang X, Li L, Liu H, Liu J. Vaccine; 2006 Apr 12; 24(16):3321-31. PubMed ID: 16472546 [Abstract] [Full Text] [Related]
16. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Gotsman I, Alper R, Klein A, Rabbani E, Engelhardt D, Ilan Y. Cancer; 2002 Jan 15; 94(2):406-14. PubMed ID: 11900226 [Abstract] [Full Text] [Related]